Literature DB >> 22949176

Gout-related health care utilization in US emergency departments, 2006 through 2008.

Rohini Garg1, Harlan R Sayles, Fang Yu, Kaleb Michaud, Jasvinder Singh, Kenneth G Saag, Ted R Mikuls.   

Abstract

OBJECTIVE: To characterize gout-related emergency department (ED) utilization using a nationally representative sample and to examine factors associated with the frequency and charges of gout-related ED visits.
METHODS: Using the National Emergency Department Sample data from 2006-2008, the weighted national frequency of gout visits was calculated along with the median ED charge and total national ED-related charges. Associations of several patient- and facility-level factors were examined with the occurrence of gout visits using multivariable logistic regression and with ED-related charges using multivariable linear regression.
RESULTS: Gout was the primary indication for 168,410 ED visits in 2006, 171,743 visits in 2007, and 174,823 visits in 2008, accounting for ∼0.2% of all visits annually and generating ED charges of more than $128 million in 2006, $144 million in 2007, and $166 million in 2008. Age, male sex, household income <$39,000, private insurance, and hospital locations in nonmetropolitan areas and the southern US were associated with an increased propensity for ED utilization in gout. Higher ED-related charges for gout were associated with female sex, age, a higher number of coded diagnoses, and a metropolitan residence.
CONCLUSION: Gout accounts for a substantial proportion of ED visits, leading to significant health care charges. Effective strategies to reduce gout burden in EDs could potentially benefit by targeting groups characterized by factors demonstrated to be related to a higher ED utilization in gout as identified by our study.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 22949176     DOI: 10.1002/acr.21837

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  24 in total

1.  Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.

Authors:  Ted R Mikuls; T Craig Cheetham; Gerald D Levy; Nazia Rashid; Artak Kerimian; Kimberly J Low; Brian W Coburn; David T Redden; Kenneth G Saag; P Jeffrey Foster; Lang Chen; Jeffrey R Curtis
Journal:  Am J Med       Date:  2018-11-29       Impact factor: 4.965

2.  The 3-Year Incidence of Gout in Elderly Patients with CKD.

Authors:  Vivian S Tan; Amit X Garg; Eric McArthur; Ngan N Lam; Manish M Sood; Kyla L Naylor
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-02       Impact factor: 8.237

Review 3.  Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications.

Authors:  Sebastian E Sattui; Angelo L Gaffo
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-05-02       Impact factor: 5.346

4.  Gout after living kidney donation: correlations with demographic traits and renal complications.

Authors:  Ngan N Lam; Amit X Garg; Dorry L Segev; Mark A Schnitzler; Huiling Xiao; David Axelrod; Daniel C Brennan; Bertram L Kasiske; Janet E Tuttle-Newhall; Krista L Lentine
Journal:  Am J Nephrol       Date:  2015-04-17       Impact factor: 3.754

Review 5.  A Systematic Review of the Economic and Humanistic Burden of Gout.

Authors:  Gemma E Shields; Stephen M Beard
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

6.  Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011.

Authors:  Sharan K Rai; J Antonio Aviña-Zubieta; Natalie McCormick; Mary A De Vera; Diane Lacaille; Eric C Sayre; Hyon K Choi
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-05       Impact factor: 4.794

7.  Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study.

Authors:  Jasvinder A Singh; Shaohua Yu
Journal:  J Rheumatol       Date:  2016-05-01       Impact factor: 4.666

8.  Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout.

Authors:  Seoyoung C Kim; Bernhard M W Schmidt; Jessica M Franklin; Jun Liu; Daniel H Solomon; Sebastian Schneeweiss
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-12       Impact factor: 4.794

9.  Trends in Emergency Department Visits and Charges for Gout in the United States between 2006 and 2012.

Authors:  Sadao Jinno; Kohei Hasegawa; Tuhina Neogi; Tadahiro Goto; Maureen Dubreuil
Journal:  J Rheumatol       Date:  2016-06-01       Impact factor: 4.666

10.  Uncovering Longitudinal Health Care Behaviors for Millions of Medicaid Enrollees: A Multistate Comparison of Pediatric Asthma Utilization.

Authors:  Ross Hilton; Yuchen Zheng; Anne Fitzpatrick; Nicoleta Serban
Journal:  Med Decis Making       Date:  2017-10-13       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.